Key Takeaways
• Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 1,562 shares at $9.1494 each.
• The total sale amount was $14,291, primarily to cover tax withholdings from restricted stock vesting.
• After the transaction, Sabatini holds 28,189 shares of Vir Biotechnology’s common stock.
Stock Sale Details
Brent Sabatini, who serves as Senior Vice President and Chief Accounting Officer at Vir Biotechnology, executed a stock sale on February 13, 2025. He sold 1,562 shares of the company at a price of $9.1494 per share, amounting to a total value of $14,291. The primary purpose of this transaction was to cover tax obligations arising from the vesting of his restricted stock units.
Post-sale, Sabatini retains a substantial stake in the company, maintaining ownership of 28,189 shares of Vir Biotechnology’s common stock. This sale comes in the context of statutory obligations employees often experience with stock vesting, particularly in situations where they have to sell a portion of their shares to meet tax liabilities.
Sabatini’s actions align with common practices among executives regarding stock sales related to tax considerations. The company’s stock performance and Sabatini’s role within the organization continue to be of interest to investors and stakeholders alike, particularly as Vir Biotechnology continues to progress in its initiatives within the biotechnology sector.
The sale, recorded in SEC Form 4, highlights the importance of transparency in financial reporting and executive transactions. Such filings are critical for maintaining regulatory compliance and ensuring that investors are aware of changes in ownership and potential impacts on stock performance.
The content above is a summary. For more details, see the source article.